Gastroenterology Preclinical Deal Benchmarks — China (2026)

Understanding Gastroenterology Deal Benchmarks at Preclinical

Preclinical Gastroenterology licensing deals in China territory command a median upfront payment of $6M, with values ranging from $2M at the low end to $11M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the gastroenterology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $35M to $131M, with a median of $83M. Royalty rates for gastroenterology assets at this stage typically fall between 2.3% and 4.5% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.